Experimental 'Body-Made' CAR-T therapy takes on Hard-to-Treat myeloma

NCT ID NCT07429721

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-phase trial tests a new gene therapy called QI-019A for people with multiple myeloma that has come back or stopped responding to treatment. The therapy works by turning a patient's own immune cells into cancer-killing cells directly inside the body. The study will enroll 24 adults to check if the treatment is safe and to get an early look at whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QI-019A (a gene therapy that turns your own immune cells into cancer fighters inside the body)
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small trial (24 people) focused on safety. The treatment may not work, and there are risks like severe immune reactions or nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

Union Hospital, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.